Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2005-02-28
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom
NCT01125306
Corneal Versus Conjunctival Delivery Using a Delivery Device
NCT00143429
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
NCT02235259
The Germinal Peptide Eye Drops in Healthy Volunteers in a Clinical Study
NCT03967548
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
NCT00509873
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xal-Ease device to be used with Xalatan eye drops
This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis warranting treatment with Xalatan eye drops.
* ambulatory and well functioning
Exclusion Criteria
* less than 40 or greater than 80 years old
* Not using Xalatan eye drops
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Augusta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medical College of Georgia
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian D. Nilson, MD
Role: PRINCIPAL_INVESTIGATOR
Augusta University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical College of Georgia Health Inc
Augusta, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Guarantor or CPI # 002533552
Identifier Type: -
Identifier Source: secondary_id
05-02-266
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.